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Background. Monocyte dysfunction may persist during 
antiretroviral therapy (ART).
Methods. Frozen peripheral blood mononuclear cells of 30 
human immunodeficiency virus (HIV)-infected ART-treated 
adults with sustained viral suppression and CD4 counts ≥500 
cells/µL were consecutively analyzed for monocyte phenotypes 
and function.
Results. Nonclassical monocytes (CD14+, CD16++), inter-
leukin (IL)-1β production, and expression of CD40 and CD86 
were lower among ART-treated HIV-infected adults relative to 
age-matched HIV-negative adults (P = .01, P = .01, and P = .02, re-
spectively). Intestinal fatty acid-binding protein, IL6, and soluble 
CD14 were higher among HIV-infected adults relative to HIV-
negative adults (P = .0002, P = .04, and P = .0017, respectively).
Conclusions. Further investigation is required to under-
stand drivers of persistent monocyte activation and dysfunction.
Keywords. HIV infection; immune activation; immune re-
sponses; long-term antiretroviral therapy; sub-Saharan Africa.
Access to antiretroviral therapy (ART) has increased steadily 
worldwide. Approximately 21.7 million people were receiving 
ART by 2017, 60% of whom live in sub-Saharan Africa (SSA) 
[1]. Although ART improves innate and adaptive immune re-
sponses, our studies reported persistent defects in T-cell function 
[2]. Persistent monocyte dysfunction may affect the quality of host 
adaptive immune responses to pathogens. Blood monocytes, a 
subset of cells of the innate immune system, represent 10% of cir-
culating leukocytes in humans. Monocytes are classified into the 
following: (1) classical monocytes (CD14++CD16− monocytes) [3] 
that are predominantly phagocytic and exhibit high peroxidase 
activity in response to lipopolysaccharide (LPS); (2) nonclassical 
monocytes (CD14+CD16++ monocyte) that remove damaged 
cells and debris from circulation and are associated with wound 
healing and resolution of inflammation [4]; and (3) intermediate 
monocytes (CD14++CD16+ monocytes) that are inflammatory 
and produce interleukin (IL)-1β and tumor necrosis factor (TNF) 
in response to LPS [5]. Monocyte activation is associated with 
spontaneous release of proinflammatory cytokines including TNF, 
IL-1β and IL-6, elevated plasma levels of soluble CD14 (sCD14), 
and D-dimers, all of which demonstrate immune activation and 
inflammation in human immunodeficiency virus (HIV)-infected 
persons [6]. Antiretroviral therapy (ART) controls HIV replica-
tion and reduces microbial translocation and immune activation; 
however, it is still unclear whether these parameters return to 
levels comparable with healthy HIV-uninfected individuals.
Microbial translocation has been described as a major driver 
of immune activation in American cohorts, although its role in 
African populations is still controversial. In a Ugandan cohort of 
ART-naive adults with opportunistic infections, microbial trans-
location was not associated with HIV disease pathogenesis and 
inflammation [7]. In a South African cohort, microbial translo-
cation and acute opportunistic infections were major drivers of 
monocyte activation during the first year of ART [8]. The role 
of monocyte activation, microbial translocation, and inflamma-
tion after several years of suppressive ART without opportun-
istic infections is yet to be understood. Given the potential role 
of monocyte activation in HIV-related cardiovascular disease risk, 
including atherogenesis and coronary artery calcium [9], there is 
a need to understand monocyte activation, its drivers, and its role 
during long-term ART in Africa. Moreover, monocyte activation 
has also been associated with accelerated immune aging among 
ART-treated adults. Therefore, we examined monocyte pheno-
types, activation markers, and functions among HIV-infected 
adults with seven years of suppressive ART and CD4 T-cell count 
restoration to ≥500 cells/μL. We also measured serum biomarkers 
of immune activation and inflammation, as well as their potential 
drivers including gut mucosal damage, microbial translocation, 
inflammation, and subclinical cytomegalovirus (CMV) infection.
METHODS
Ethics Approval and Consent to Participate 
Ethical approval was sought from the School of Biomedical 
Sciences Makerere University College of Health Sciences 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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Research and Ethics Committee. All participants provided 
written informed consent for storage and future use of their 
samples in studies to understand host immune recovery during 
ART.
Study Design
A comparative sample-based, cross-sectional study was con-
ducted within the Infectious Diseases Institute HIV treatment 
research cohort. In 2004–2005, a cohort of 559 adults ≥18 years 
(386 [69%] female) with a median age of 36 (interquartile range 
[IQR], 21–44) years and a median CD4 count of 98 (IQR, 
21–163) cells/μL initiated ART. Viral load and CD4 counts were 
estimated every six months. All patients received cotrimoxazole 
(or dapsone) prophylaxis. Adherence to ART was encouraged 
by at least three individual counseling sessions. Patients had 
monthly physician reviews to monitor adherence to medica-
tion, toxicities, and acute infections.
Study Participants
After seven  years of ART, 121 adults who remained on first-
line therapy with undetectable viral loads (<50 copies) from 
the first measurement at six  months post-ART and without 
opportunistic infections in the preceding six months were de-
scribed by CD4 count increases from the nadir CD4 count. 
All the (30 [26/87%] female and median age 40 [IQR, 38–46] 
years) patients in the highest quartile of CD4 recovery (581–
1572 cells/µL), normal CD4 counts for healthy HIV-uninfected 
Ugandans, were included. Stored peripheral blood mononu-
clear cells (PBMCs) and plasma were used. All parameters were 
compared with 30 age-matched, healthy, HIV-negative adults 
(±5  years) from the same communities. Healthy adults were 
selected randomly as they attended nonillness visits for health 
education and voluntary HIV testing. Sixty-three percent (19 of 
30) were female and the median age was 35.5 (IQR 32.5–42.0) 
years (Supplemental Table 1).
Experimental Procedures
Flow Cytometry Assays
Cryopreserved PBMCs were snap-thawed and washed with R20 
(complete Roswell Park Memorial Institute [RPMI] 1640 me-
dium supplemented with 20% fetal bovine serum [FBS]). The 
cells were counted and rested for 4 hours at 37°C in a 5% CO2 
incubator. Eighty-five percent average viability was achieved 
after resting.
Surface Staining
Cells were stained with CD3 BV510, CD56 BV510, CD19 
BV510, CD14 PerCP Cy5.5, CD16 BV605, CD86 APC, CD40 
APC-H7, and HLAR-DR APC-R700 (BD Biosciences). Surface 
staining was done at 4°C for 30 minutes with saturating con-
centrations of antibodies in the presence of fixable live/dead 
stain (Invitrogen). Cells were fixed and acquired using the 
LSRII flow cytometer (FACSDiva software 8.0; BD Bioscience). 
At least 500 000 events of lymphocytes were acquired. CD3 ex-
pression was used to exclude T cells, CD19 excluded B cells, 
and CD56 excluded natural killer cells. Monocyte subsets 
were described by intensity of expression of CD14 and CD16 
markers [5]. CD14++CD16− cells were denoted classical mono-
cytes, CD14++CD16+ were denoted intermediate monocytes, 
and CD14+CD16++ were denoted nonclassical monocytes 
(Supplemental Figure 1).
Intracellular cytokine staining was done after stimulation 
of 2 × 106 PBMCs with 1 ng/mL LPS at 37°C in a 5% CO2 in-
cubator for 4 hours in the presence of 1:250 ng/mL brefeldin 
A.  Lipopolysaccharide stimulation was optimized at 1  ng/mL 
after trials with 0.5, 1, and 2  ng/mL. Cells were washed with 
FACS buffer (5% FBS, 0.01% sodium azide, and 1× phosphate-
buffered saline. Cells were then stained with TNF PE-CY7, IL-1β 
PE, and IL-6 BV421 (BD Biosciences). Samples were acquired 
on an LSRII using BD FACSDiva software 8.0. At least 100 000 
events of the monocyte gate were acquired (Supplemental 
Figure 1).
Enzyme-Linked Immunosorbent Assays 
Cryopreserved plasma was thawed and analyzed for sCD14 
(catalog no. DC140), intestinal fatty acid-binding protein 
([IFAB-P] catalog no. DY3078), LPS binding protein ([LBP] 
catalog no. KA0448), and IL-6 (catalog no. D6050) (all from 
R&D Systems, Abingdon, UK). We also determined circu-
lating D-dimer levels (reference no. EHDDIMER; Thermo 
Fisher Scientific), LPS (catalog no. MBS2703401; MyBioSource, 
Inc.), and CMV antibodies (catalog no. abx354612; Abbexa 
Cambridge, UK). RealStar CMV PCR Kit (Altona Diagnostic, 
Hamburg, Germany) was used for CMV viral load.
Data Management and Analysis
Flow data was analyzed using FlowJo software (version 10.1; Tree 
Star). Comparisons and graphs were made using Graph Prism 6 
and tested using Mann-Whitney U test for non-parametric tests 
with statistical significance at P ≤ .05.
RESULTS
Clinical and demographic characteristics were similar among 
the ART-treated adults (median age 40 [IQR, 38–46] years and 
26 [87%] female) and age-matched healthy HIV-negative adults 
(median age 35.5 [IQR, 32.5–42] years and 19 [63%] female) 
(Supplemental Table 1).
Monocyte Phenotype and Function
Proportions of nonclassical monocytes (CD14+, CD16++) were 
lower in the ART-treated HIV-infected individuals than in their 
HIV-negative counterparts (P = .01); classical (CD14++, CD16−) 
and intermediate monocyte (CD14++CD16+) subsets were sim-
ilar (Figure 1A). CD86 and CD40 expression by nonclassical 
monocytes after 4-hour LPS stimulation was lower among 
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HIV-infected than HIV-negative individuals (P  =  .0001 and 
P = .02, respectively) (Figure 1B). We observed lower IL-1β pro-
duction by classical monocytes among ART-treated HIV-positive 
relative to healthy HIV-negative adults (P = .04) (Figure 2A).
Monocyte Activation and Inflammation
Serum IL-6 was higher among ART-treated HIV-infected 
than HIV-negative individuals (P  =  .04), and serum levels 
of D-dimers were comparable in both groups (Figure 2B). 
Circulating sCD14 was higher among ART-treated HIV-
infected (median 12754.2 [IQR, 8368.3–14 940.8] pg/mL) than 
among healthy HIV-negative individuals (median 9010 [IQR, 
5549.0–12298.7] pg/mL; P = .002) (Supplemental Table 2).
Drivers of Activation and Inflammation
Soluble I-FAB-P was higher among ART-treated HIV-infected 
than HIV-negative individuals (P =  .0002). Serum levels of LBP 
and LPS were lower among ART-treated HIV-infected than HIV-
negative individuals (P  =  .0018) and (P  =  .0006), respectively. 
Serum CMV viremia and immunoglobulin G levels were compa-
rable among ART-treated HIV-infected relative to HIV-negative 
individuals (Supplemental Table 2).
DISCUSSION
Monocyte Phenotypes and Function
Low circulating nonclassical monocytes among ART-treated 
adults is likely due to continuous death of this phenotype, which 
is more permissive to HIV infection due to its high expression 
of CCR5. The nonclassical monocytes have high expression of 
CD16+ and FcγRIII and are known to have a unique ability of 
patrolling resting vasculature to remove debris and repair dam-
aged tissue [10]. The low nonclassical monocytes exhibited by 
ART-treated HIV-infected adults without coinfections may 
play a role in the noncommunicable disease risk associated with 
chronic HIV disease [11].
Low interleukin-1β (IL-1β) production by classical mono-
cytes of HIV-infected individuals demonstrated impaired mon-
ocyte immune responses to invading antigens. Interleukin-1β 
contributes to the control of bacterial, viral, parasitic, and fungal 
infections and has been associated with protection against tu-
berculosis [12]. Oversecretion of 1L-1β, IL-6, and TNF-α in 
ART-naive patients was observed in a French cohort (MANIF 
2000 Study Group), which reduced during ART. Although cy-
tokine production had greatly decreased, the cells still produced 
good amounts of cytokines upon in vitro LPS stimulation. 
Lipopolysaccharide did not stimulate significant production of 
IL-1β by monocytes in our study. We postulate that exposure 
to infections in SSA causes immune activation with subsequent 
anergy.
Co-stimulatory molecules CD40 and CD86, expressed on 
monocytes and other antigen presenting cells, are critical in 
ensuring optimal antigen presentation to T-cells and effective 
activation. Engagement of co-stimulatory ligands (CD40L and 
CD86) boosts antigen-stimulated cytokine production, clonal 
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Figure 1. Monocyte phenotype distribution in peripheral blood and expression of costimulatory molecules (CD86 and CD40) nonclassical monocytes. (A) Monocyte pheno-
types among the antiretroviral therapy (ART)-treated human immunodeficiency virus (HIV)+ individuals with CD4 count of >500 cell/µL and supressed viral load in comparison 
with the age-matched, healthy, HIV-negative population from the same community. (B) CD86 and CD40 expression on nonclassical monocytes of ART-treated HIV-infected 
and HIV-negative individuals after 1 ng/mL lipopolysaccharide stimulation. The Mann-Whitney U test was used to compare the monocyte proportions between HIV-infected 
and healthy subjects.
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expansion of T cells, and their differentiation into effector 
cells [13]. Lower expression of co-stimulatory ligands in HIV-
infected individuals may be associated with low T-cell effector 
functions. Stability of the antigen presentation process during 
HIV infection has been described based on major histocompat-
ibility complex (MHC)-II expression [14], although expression 
of CD40 and CD86 had not been evaluated.
Monocyte Activation and Inflammation
Monocyte activation correlates with impairment of monocyte 
function, similar to our observation of lower expression of 
costimulatory molecules with lower IL-1β production among 
ART-treated HIV-infected adults. Despite evidence of mucosal 
damage among ART-treated HIV-infected adults without evi-
dence of microbial translocation, sCD14 marker of monocyte 
activation was high. In the absence of opportunistic infections 
including CMV infection, persistent monocyte activation could 
be attributed to replication of HIV in the reticuloendothelial 
system [8]. Although several studies have demonstrated re-
duction of circulating LPS during ART, some previous reports 
showed lower circulating LPS among HIV-infected individ-
uals relative to HIV-negative controls. Moreover, Redd et  al 
[7] suggested that the effect of microbial translocation on HIV 
might not be subclinical endotoxemia but rather the variable 
host responses to circulating microbial products. There is also 
evidence that healthy HIV-negative individuals in SSA may 
have a subclinical environmental enteropathy, which might be 
responsible for the microbial translocation observed in HIV-
negative adults [15]. Human immunodeficiency virus disease 
adds an increase in crypt depth and lactulose permeation par-
ticularly in advanced disease with CD4 cells <200 cells/μL [15]. 
Low levels of circulating LPS after seven years of ART could be 
due to prolonged cotrimoxazole and recurrent antibiotic use, 
which modify gut microbial communities.
High levels of circulating IL-6 demonstrate persistent systemic 
inflammation, and dysregulated production of IL-6 plays a key 
role in chronic inflammation and autoimmunity. Unfortunately, 
persistent inflammation and activation during ART is associ-
ated with increased risk of fatal nonacquired immune deficiency 
syndrome illnesses among adults aging with HIV [9]. For ex-
ample, circulating CD16+ monocytes were associated with ath-
erogenesis and greater coronary artery calcium [9]. Our results 
are comparable with previous reports that immune activation 
decreased with duration of ART although it did not return to 
levels  reduction of monocyte activation to levels comparable 
to HIV-negative individuals has been observed after 48 weeks 
of integrase inhibitor-based ART in the United States. More 
studies are needed to understand drivers and potential modu-
lators of monocyte activation and inflammation, particularly 
among HIV-infected adults in SSA where the landscape of ART 
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Figure 2. Interleulin (IL)-1β production by the classical monocytes and circulating inflammation markers IL-6 and D-dimer. (A) A comparison of IL-1β production among anti-
retroviral therapy (ART)-treated human immunodeficiency virus (HIV)-infected and healthy HIV-negative individuals from the same community. (B) Circulating IL-6 and D-dimer 
among ART-treated HIV-infected and HIV-negative individuals. The Mann-Whitney U test was used to compare parameters between HIV-infected and healthy subjects, with 
statistical significance at P < .05.
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regimen, extent of disease at ART initiation, and endemic infec-
tious agents are variable. As a limitation of our cross-sectional 
study design, we did not have longitudinal data. Furthermore, 
using stored samples may not capture prevailing biologic events 
that can only be demonstrable at physiologic conditions.
CONCLUSIONS
Monocyte activation with impaired antigen presentation and 
IL-1β production were observed among ART-treated HIV-
infected adults after 7  years of suppressive ART. Commonly 
implicated drivers of immune activation such as CMV viremia 
and microbial translocation were absent, hence there is a need 
to explore other potential drivers of monocyte activation and 
inflammation among aviremic ART-treated adults.
SUPPLEMENTARY DATA
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
Supplemental Table 1. Demographic characteristics of 
human immunodeficiency virus (HIV)-infected adults after 
7  years of suppressive antiretroviral therapy (ART) and age- 
and gender-matched health HIV-negative counterparts from 
the same community.
Supplemental Table 2. Comparison of levels of serum bio-
markers of microbial translocation and monocyte activation 
between antiretroviral therapy (ART)-treated and human im-
munodeficiency virus (HIV)-negative individuals.
Supplemental Figure 1. Monocyte gating strategy. (A) 
shows how monocytes were gated using light scatter character-
istics and the exclusion of T cells, B cells, natural killer (NK) 
cells, and dead cells by gating on the CD3−, CD19−, CD56−, and 
Aqua− cells, respectively. HLADR+ gate shows HLADR+ mono-
cytes and gating strategy for the different monocyte subsets. 
CD16++ the nonclassic monocytes (NC), CD14++, CD16+ inter-
mediate monocytes (IN), and CD14++ classic monocytes (C). 
(B) shows the gating strategy for interleukin (IL)-1beta, tumor 
necrosis factor (TNF), and IL-6 production upon stimulation 
of peripheral blood mononuclear cells (PBMCs) with 1 ng/mL 
lipopolysaccharide (LPS).
Supplemental Figure 2. Gating strategy for costimulatory 
molecules CD86 and CD40 by nonclassic monocytes of antire-
troviral therapy (ART)-treated human immunodeficiency virus 
(HIV)-infected and HIV-negative individuals after 1 ng/mL lip-
opolysaccharide (LPS) stimulation.
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